Key Insights

Highlights

Success Rate

25% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

34.6%

9 terminated out of 26 trials

Success Rate

25.0%

-61.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

233%

7 of 3 completed with results

Key Signals

7 with results25% success

Data Visualizations

Phase Distribution

23Total
Not Applicable (1)
Early P 1 (1)
P 1 (12)
P 2 (9)

Trial Status

Active Not Recruiting9
Terminated9
Recruiting5
Completed3

Trial Success Rate

25.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (26)

Showing 20 of 20 trials
NCT04462406Phase 2Active Not Recruiting

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

NCT03769155Phase 1Active Not Recruiting

VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma

NCT03554083Phase 2Completed

Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

NCT06151847Phase 2Completed

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

NCT03816332Phase 1Active Not Recruiting

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

NCT04902040Phase 1Terminated

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

NCT05039801Phase 1Recruiting

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT04708418Phase 2Active Not Recruiting

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

NCT04527549Phase 2Terminated

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

NCT04221438Phase 2Terminated

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

NCT04119024Phase 1Recruiting

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

NCT05098210Phase 1Recruiting

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

NCT03819296Phase 1Recruiting

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

NCT04940299Phase 2Active Not Recruiting

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

NCT04990726Active Not Recruiting

Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

NCT05176470Phase 1Active Not Recruiting

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

NCT03865212Phase 1Terminated

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

NCT07259304Recruiting

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

NCT03677739Not ApplicableActive Not Recruiting

Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families

NCT04516122Terminated

Bone Loss in Melanoma Survivors Receiving Immunotherapy

Scroll to load more

Research Network

Activity Timeline